|
|
Vaccine Detail
|
Neoantigen-loaded Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Neoantigen-loaded Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: neoantigens (NCT04147078; NCT04912765; NCT03871205; NCT03674073; NCIT_C141422)
- Immunization Route: subcutaneous injection
- Description: This is a personalized, peptide-based therapeutic dendritic cell (DC) vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. (NCIT_C141422) Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. (NCT03871205) Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. (NCT04147078) The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). (NCT03674073) It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM). (NCT04912765)
|
| Host Response |
|
|
| References |
NCIT_C141422: Neoantigen-loaded Autologous Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422]
NCT03674073: A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT03674073]
NCT03871205: Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer [https://clinicaltrials.gov/study/NCT03871205]
NCT04147078: Personalized DC Vaccine for Postoperative Cancer [https://clinicaltrials.gov/study/NCT04147078]
NCT04912765: Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC [https://clinicaltrials.gov/study/NCT04912765]
|
|
